Skip to main content
. 2024 May 27;25(11):5817. doi: 10.3390/ijms25115817

Figure 3.

Figure 3

Clinical score (left axis) and TEER (right axis) in UC (A) and CD (B) patients before and after 24 weeks and 52 weeks of treatment with vedolizumab (VDZ). Data are mean values per patient at baseline and after VDZ treatment; in (A,B): n = 16 UC and n = 4 CD patients at baseline, n = 14 UC and n = 4 CD patients after 24 weeks of VDZ treatment, and n = 8 UC and n = 4 CD patients after 52 weeks of VDZ treatment. Two UC patients had no endoscopic scores after 24 weeks of VDZ treatment. For the comparison of the TEER, a one-way analysis of variance (ANOVA) followed by Holm–Sidak’s multiple comparison post hoc test was used. For the comparison of the endoscopic scores, the Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test was used. * p < 0.05, *** p < 0.001 and **** p < 0.0001 vs. IBD baseline (post hoc test ANOVA).